分子诊断产品开发商Mdxhealth将收购其Exosome Diagnostics 业务-动脉网

Bio-Techne Announces Exosome Diagnostics Divestiture

CISION 等信源发布 2025-08-06 04:30



可切换为仅中文







MINNEAPOLIS

明尼阿波利斯

，

Aug. 5, 2025

2025年8月5日

/PRNewswire/ -- Bio-Techne Corporation (NASDAQ:

TECH

技术

) today announced an agreement where Mdxhealth SA will acquire its Exosome Diagnostics Inc. business, including the ExoDx Prostate (EPI) test, CLIA-certified clinical laboratory and related assets. Bio-Techne will retain access to the proprietary exosome-based technology for ongoing kit development in its precision diagnostics growth pillar..

）今天宣布了一项协议，根据该协议，Mdxhealth SA将收购其Exosome Diagnostics Inc.业务，包括ExoDx Prostate（EPI）测试、CLIA认证的临床实验室及相关资产。Bio-Techne将继续保留对基于外泌体的专有技术的访问权，以支持其在精准诊断增长支柱中的试剂盒开发。

'Mdxhealth is the ideal acquirer of our ExoDx Prostate test and CLIA-certified laboratory,' said

“Mdxhealth是我们ExoDx前列腺测试和CLIA认证实验室的理想收购者，”

Kim Kelderman

金·凯尔德曼

, President and Chief Executive Officer of Bio-Techne. 'Mdxhealth has made several strategic moves over the past few years to position the company as a leader in urology and prostate cancer diagnostics. The addition of ExoDx Prostate to their portfolio accelerates their leadership in this market.'

生物技术公司总裁兼首席执行官。“Mdxhealth在过去几年中采取了几项战略举措，将公司定位为泌尿学和前列腺癌诊断领域的领导者。ExoDx Prostate的加入进一步加速了他们在这一市场的领导地位。”

Kelderman continued, 'Following this transaction, Bio-Techne will strengthen its foundation as a developer of innovative, high value, high margin products, tools and reagents for the life science research and clinical diagnostics markets. This repositioning of the portfolio enables Bio-Techne to direct additional investments to further strengthen this foundation, while creating an immediate uplift to our sector leading operating margin profile.'.

凯尔德曼继续说道：“通过此次交易，Bio-Techne 将巩固其作为生命科学研究和临床诊断市场创新、高价值、高利润率产品、工具和试剂开发者的地位。此次产品组合的重新定位使 Bio-Techne 能够引导额外的投资进一步巩固这一基础，同时为我们在行业中领先的营业利润率带来立竿见影的提升。”

'ExoDx Prostate is a strong strategic fit with our rapidly growing urology and prostate cancer diagnostic business,' said

“ExoDx Prostate 与我们快速发展的泌尿科和前列腺癌诊断业务非常契合，”

Michael McGarrity

迈克尔·麦加里蒂

, Chief Executive Officer of Mdxhealth. 'The ExoDx Prostate test equips men with information to make better decisions and avoid unnecessary and potentially dangerous prostate biopsies. Bio-Techne has done a tremendous job delivering this necessary information to patients and growing the base of physicians leveraging this tool.

，Mdxhealth的首席执行官。“ExoDx前列腺测试为男性提供了更好的决策信息，帮助他们避免不必要的、可能危险的前列腺活检。Bio-Techne在向患者传递这一必要信息以及扩大使用该工具的医生群体方面，做得非常出色。

We are looking forward to building on this success.'.

我们期待在此成功的基础上继续努力。

Under the terms of the agreement, Bio-Techne will receive

根据协议条款，Bio-Techne将获得

$5 million

500万美元

in MDXH stock combined with future considerations. The transaction is expected to be completed during the first quarter of Bio-Techne's fiscal 2026.

在MDXH股票结合未来考量的交易中，预计该交易将在Bio-Techne 2026财年第一季度完成。

Bio-Techne will discuss this transaction, as well as its fourth quarter fiscal 2025 performance on its earnings call tomorrow,

Bio-Techne 将在明天的财报电话会议上讨论此次交易以及其 2025 财年第四季度的表现。

August 6

8月6日

, 2025, at

，2025年，于

8:00 a.m. CDT

早上8点（中部夏令时间）

. To listen, please dial 1-800-274-8461 or 1-203-518-9814 (for international callers), and reference conference ID: TECHQ4. The earnings call can also be accessed via webcast through the following link

要收听，请拨打1-800-274-8461或1-203-518-9814（国际呼叫者），并引用会议ID：TECHQ4。财报电话会议也可以通过以下链接以网络广播形式访问。

https://investors.bio-techne.com/ir-calendar

。

Forward Looking Statements:

前瞻性声明：

Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. Forward looking statements in this press release include statements regarding our belief about the impact of our pending divestiture of Exosome Diagnostics Inc.

我们的新闻稿可能包含《私人证券诉讼改革法案》所指的前瞻性陈述。这些陈述涉及可能影响实际运营结果的风险和不确定性。本新闻稿中的前瞻性陈述包括关于我们对即将剥离Exosome Diagnostics Inc.的影响的看法的陈述。

The following important factors, among others, have affected and, in the future, could affect the Company's actual results: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships..

以下重要因素，除其他外，已经影响并且未来可能继续影响公司的实际结果：新品牌和营销计划的效果、新业务和领导层的整合、新产品的推出与接受程度、公司客户对研究类型的资金投入与关注、生物技术研究产品生产商日益增多及其相关价格竞争的影响、总体经济状况、汇率波动的影响，以及公司及其投资或建立战略关系的公司所进行的研究和产品开发工作的成本与结果。

For additional information concerning such factors, see the section titled 'Risk Factors' in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events.

有关这些因素的更多信息，请参阅公司向证券交易委员会提交的Form 10-K年度报告和Form 10-Q季度报告中题为“风险因素”的部分。由于新信息或未来事件，我们不对我们在新闻稿中作出的任何前瞻性声明承担更新或修改的义务。

Investors are cautioned not to place undue emphasis on these statements..

投资者应注意不要对这些声明过分强调。

About Bio-Techne

关于Bio-Techne

Bio-Techne Corporation (NASDAQ:

Bio-Techne Corporation (纳斯达克:

TECH

技术

) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses.

）是一家全球生命科学公司，为科研和临床诊断界提供创新工具和生物活性试剂。Bio-Techne 产品助力对生物过程以及特定疾病的性质和进展的科学研究。它们有助于药物发现工作，并提供实现准确临床测试和诊断的手段。

With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately .

由于其产品组合中有数十万种产品，Bio-Techne 的收入大约为 .

$1.2 billion

12亿美元

in net sales in fiscal 2024 and has over 3,000 employees worldwide. For more information on Bio-Techne and its brands, please visit

在2024财年净销售额，并在全球拥有超过3,000名员工。有关Bio-Techne及其品牌的更多信息，请访问

https://www.bio-techne.com

or follow the Company on social media at:

或在社交媒体上关注公司：

Facebook

，

领英

，

Twitter

或

YouTube

。

Contact:

联系：

David Clair

大卫·克莱尔

, Vice President, Investor Relations & Corporate Development

副总裁，投资者关系与企业发展

david.clair@bio-techne.com

612-656-4416

About mdxhealth®

关于mdxhealth®

Mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers and prognosis of recurrence risk.

Mdxhealth是一家商业阶段的精准诊断公司，提供可操作的分子诊断信息，以个性化癌症的诊断和治疗。该公司测试基于专有的遗传、表观遗传（甲基化）和其他分子技术，协助医生诊断泌尿系统癌症并预测复发风险。

The Company's European headquarters are in Herstal, .

公司的欧洲总部在赫斯塔尔。

Belgium

比利时

, with laboratory operations in Nijmegen,

，在奈梅亨设有实验室运营，

The Netherlands

荷兰

, and U.S. headquarters and laboratory operations based in

，以及位于美国的总部和实验室设施

Irvine, California